Prof Giuseppe Saglio speaks about the DASISION trial which compares dasatinib with imatinib as initial treatment for patients with newly diagnosed chronic myeloid leukaemia in chronic phase (CML-CP). Cardiovascular disease is an important comorbidity in some patients with CML-CP and this study assessed the effect the drugs had on efficacy and safety. Prof Saglio outlines the results of this study and explains the role he believes imatinib and dasatinib have to play in the treatment of CML-CP.